AFP and PIVKA-II were significantly lower in patients without HCC recurrence compared to patients with HCC recurrence, 6.4 ng/mL (IQR 4.3–14.7) vs. 25.2 ng/mL (IQR 8.5–1284.4, p < 0.001), and 68.0 mAU/mL (IQR 37.8–163.5) vs. 217.0 mAU/mL (IQR 79.0–836.0, p = 0.005), respectively. This evidence concerns the gene AFP and hepatocellular carcinoma.